GlassScriptPhysician profile
Coby N Harrison
NPI 1891054359
$16,331.55
in general payments reported to CMS, 2019-2025
47 companies · $2,657 in 2025
The $2,657 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $1,541 · 2021: $2,827 · 2022: $2,511 · 2023: $2,317 · 2024: $2,877 · 2025: $2,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,778 · Education: $73.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,777.67 |
| Education | $73.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,989.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $2,372.00 | 2021-2025 | |
| Pfizer INC. | $1,195.08 | 2019-2025 | |
| Lilly USA, LLC | $1,100.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $830.53 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $821.42 | 2019-2024 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $720.63 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $587.81 | 2019-2025 | Evenity, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $569.13 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $541.07 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Bayer Healthcare Pharmaceuticals INC. | $423.86 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $264.64 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $235.03 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $224.59 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $223.99 | 2019-2025 | Trintellix |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coby Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.